Navigation Links
Shire's Quarterly Revenues Grow by 25% to $1 Billion for the First Time
Date:7/28/2011

ns in Q2 2011 compared to Q2 2010, and the inclusion in Q2 2010 product sales of previously deferred revenues relating to launch stocking shipments made in 2009.

FOSRENOL - Hyperphosphatemia

Product sales of FOSRENOL were flat as the effect of price increases taken since Q2 2010 and positive foreign exchange offset lower US prescription demand due to a fall in market share. On a CER basis sales were down quarter on quarter by 5%.

2.      Royalties

Year on year growth Royalties to Product Shire $M Royalties CER ADDERALL XR 1.00 26.9 -2% -2% FOSRENOL 1.00 12.4 107% 107% 3TC(R) and Zeffix(R) 1.00 11.3 -70% -70% Other 1.00 12.8 15% 5% Total 1.00 63.4 -23% -25%

Royalty income decreased in Q2 2011 compared to Q2 2010 as higher royalties on FOSRENOL were more than offset by lower royalties from 3TC and Zeffix.

Royalty income from 3TC and Zeffix continues to be adversely impacted by increased competition from other products. Additionally, for certain territories in the second quarter of 2011 Shire did not recognise 3TC royalties for the current quarter, and reversed 3TC royalty income recognised in the prior two quarters, due to a difference of opinion between GlaxoSmithKline ("GSK") and Shire about how the relevant royalty rate should be applied given the expiry dates of certain patents. GSK and Shire are holding discussions in order to clarify this discrepancy.

FOSRENOL royalties increased in Q2 2011 due to higher demand for the product by Shire's Japanese partner given supply issues of a competitor resulting from the Japanese earthquakes earlier in 2011.

3.      Financial details

Cost of product sales

% of % of product product Q2 2011 sales Q2 2010 sales $M $M Cost of product sales (US GAAP) 143.7 14% 119.1 16% Transfer of manufacturing from Owings Mills (2.8) (7.4) Deprecia
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. Neogen Reports 27% Increase in Quarterly Net Income
2. Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
3. Microbix Has Best-Ever Quarterly Sales
4. Amylin Pharmaceuticals Announces Third Quarter Product Revenues; Quarterly Update Conference Call Canceled
5. China-Biotics, Inc. Reports Record Quarterly and Annual Revenue Growth for Fiscal Year 2010
6. Shires Replenished Portfolio Drives Excellent Quarterly Performance
7. Quest Diagnostics Declares Quarterly Cash Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Schering-Plough Declares Quarterly Dividends on Common Shares and Mandatory Convertible Preferred Stock
10. Abbott Declares 343rd Consecutive Quarterly Dividend
11. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... -- According to a new market research ... Electrophoresis, Agarose & Polyacrylamide Gel, Capillary Electrophoresis, Isoelectric Focusing, ... by End User - Global Forecast to 2020", published ... around $1.98 Billion by 2020 with a CAGR of ... Browse 226 ma rket data T ...
(Date:5/21/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... develops and commercializes proprietary technologies and products for advanced ... for the second fiscal quarter ended March 31, 2015. ... to advance business with our existing customers and to ... and CEO of SQI. "The delivery of a fully ...
(Date:5/21/2015)... NEW YORK , May 21, 2015  Prima ... biotechnology company that is striving to become a leader ... of cancer, recently announced that the final CVac data ... has shown a clear trend for a clinically meaningful ... ("SOC") in second remission patients. In the ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Correction Continues after Big Move - BrokerBank Securities, Inc. 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... have issued a warning that it is too early ... Published on Friday in the journal Science, signatories include ... Netherlands, India, Germany and the UK. The UK is ... East Anglia and Dr Richard Lampitt of Southampton Universitys ...
... BIRMINGHAM, Ala., Jan. 10 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... M.D.,has joined BioCryst as a consultant and interim ... years of expertise in global pharmaceutical,development to his ... ), "We are very pleased to have ...
... Ky., and Newport News, Va. Also ... ... excellence and remarkable achievements in its,community, Harborview Medical Center of Seattle is ... of the most esteemed,honors of excellence in community service in healthcare. As ...
Cached Biology Technology:BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 2BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 3BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 2Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 3Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 4Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 5Harborview Medical Center in Seattle Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 6
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2
... had sex in over 40 million years of existence ... new research published today. The study challenges the assumption ... provides scientists with new insight into why species evolve ... in PLoS Biology, focuses on the study of bdelloid ...
... Borstel, cancer is a metaphorical example of the perfect invasion ... landed on a deserted island in the Galapagos Archipelago, the ... many mutations through many generations to establish itself as an ... is there, like any newly stabilized species in different ecological ...
... cancer cells from being forced to devour themselves, removing ... growth, researchers at The University of Texas M. D. ... Molecular Cancer Research. , The protein tissue transglutaminase, known ... researchers at M. D. Anderson and elsewhere to be ...
Cached Biology News:No sex for 40 million years? No problem 2New bird, bat species revealed by extensive DNA barcode studies 2Protein found to shield pancreatic cancer cells from self-destruction 2
... The BioPrime Plus Array CGH Genomic Labeling ... enable reproducible labeling of genomic DNA samples ... in both indirect and direct labeling formats, ... Systems provide a flexible solution to your ...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
Biology Products: